BRAF V600E Mutations In Papillary Thyroid Carcinoma
- Conditions
- Papillary Thyroid Carcinoma
- Registration Number
- NCT01417442
- Lead Sponsor
- Bezmialem Vakif University
- Brief Summary
The purpose of this study is to determine whether BRAF V600E mutation in our patients with papillary thyroid cancer has an association with poor prognosis.
- Detailed Description
Papillary thyroid carcinoma (PTC) is the most common type of thyroid malignancy and BRAF V600E mutation is the most common genetic alteration identified in PTC, ranging from 25 to 80%, with the average rate about 45%. Various studies demonstrated a relationship between BRAF V600E mutation and aggressive characteristics of the cancer, including the worse patient prognosis. But,there are no studies from Turkey regarding this topic. So the investigators will examine BRAF V600E mutation in our patients with PTC and try to assess the role of this mutation in prognosis and further management of the patients.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
- Patients with papillary thyroid cancer
- Patients who do not want to be a part of this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method BRAF V600E MUTATION 2 years
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Yeliz Emine Ersoy
🇹🇷Istanbul, Turkey
Yeliz Emine Ersoy🇹🇷Istanbul, Turkey